Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...

"Exelixis and MSD to trial cancer therapies together in clinical collaboration" was originally created and published by ...

Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive ...

Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland. In final draft ...

Okta, Inc. , the leading independent Identity partner, today announced that it will webcast the Opening Keynote of Oktane and Investor Summit on October 16, 2024. Each presentation will be webcast ...

On October 14, 2024, MRK announced a clinical development collaboration with Exelixis to evaluate the investigational drug ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

S ean Korbitz was a 20-year-old college student when he first started experiencing symptoms of von Hippel-Lindau syndrome, ...

India on Thursday weighed in on the ongoing diplomatic spat with Canada by holding the Trudeau administration responsible for 'precipitating' the current diplomatic fallout while acknowledging the ...